Table of Contents
The list contains Europe and U.S. based companies, but revenues considered are strictly from only USA. To maintain the consistency of reporting, all revenue figures are converted in USD billion for this analysis.
- Pfizer Inc. : USD 25.32 Billion
- Johnson & Johnson : USD 23.28 Billion
- Roche Holding AG : USD 22.76 Billion
- AbbVie Inc. : USD 21.52 Billion
- Amgen : USD 18.28 Billion
- Novartis AG : USD 17.56 Billion
- Merck & Co., Inc. : USD 16.60 Billion
- Gilead Sciences, Inc. : USD 16.20 Billion
- Sanofi S.A : USD 13.15 Billion
- Bristol-Myers Squibb : USD 12.58 Billion
U.S. Pharmaceuticals Industry Analysis and Trends 2023
Browse Report [11]
1 . 1.Pfizer Inc
Pfizer's 2018 revenue from U.S market [13]was $25.32 billion, a decrease of -2.75%, compared to 2017. Pfizer Inc. registered highest revenue from USA market which accounted for 47.21% of its total sales in FY 2018.On various product fronts, industry-wide pricing challenges and generic competition are few of the challenges for company in U.S. market.
2 . 2.Johnson & Johnson
Johnson & Johnson registered highest revenue from USA [14]market at USD 23.28 billion (Pharma division) which is an increase of +8.43%, compared to 2017. Sales by U.S. companies were $41.9 billion (in all franchise) in 2018, $39.9 billion in 2017 and $37.8 billion in 2016. This represents increases of 5.1% in 2018, 5.4% in 2017 and 6.0% in 2016.
3 . 3.Roche Holding AG
Roche Holding AG reported revenue of USD 22.76 billion for the FY 2018 from U.S. market [15]which saw an increase of 13.35% compared to FY 2017. In the U.S., sales increase led by Ocrevus, Perjeta and Lucentis. Ocrevus sales were supported by continued strong new patient demand as well as follow-up treatments.
4 . 4.AbbVie Inc.
AbbVie Inc. reported U.S. revenue of USD 21.52 billion for the FY 2018 which saw an increase of 17.9% compared to FY 2017. Company's global sales were impacted [16]by the launch of several direct biosimilar drugs. These drugs are launched at much cheaper price anticipated by AbbVie resulting decline in sales in Europe and other international markets.
5 . 5.Amgen Inc.
Amgen's full year, U.S. revenue [17] increased by 1.27 percent to $18.28 billion, from 2017. Company's product sales grew 8 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) registered double-digit growth.
6 . 6.Novartis AG
Novartis AG reported revenue of USD 17.56 billion for the FY 2018 which saw an increase of 3.69% compared to FY 2017.Novartis [18] has decided to shed its Alcon eye-care unit and U.S. generics pills business to focus on newer high-tech drugs.
7 . 7.Merck & Co., Inc.
Merck reported revenue [19] of USD 16.60 billion for the FY 2018 which saw an increase of 4.76% compared to FY 2017. Company's overall revenue is expected to increase by 5.68% and reach USD 44.700 billion by FY 2019.Looking into 2019, Merck said it sees non-GAAP earnings of between $4.57 and $4.72 per share on worldwide sales of between $43.2 billion and $44.7 billion.
8 . 8.Gilead Sciences, Inc.
Gilead Sciences, Inc. (Gilead) is a U.S. based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases. Gilead reported revenue [20] of USD 16.20 billion for the FY 2018 which saw decrease of 10.56% compared to FY 2017.
9 . 9.Sanofi S.A.
Sanofi S.A. registered pharma revenue [21] of USD 13.15 from USA market which is a decrease of 2.66%, compared to 2017. Although strong performances of Dupixent® and Aubagio®, together with the consolidation of Eloctate® and Alprolix® sales have partly offset the lower sales of the Diabetes franchise and of sevelamer.
10 . 10.Bristol-Myers Squibb Company
Bristol-Myers Squibb's revenue from U.S. [22] market valued at USD 12.58 billion, which is a 11% higher than FY 2017. For 4th quarter U.S. revenues increased 16% to $3.3 billion in the quarter compared to the same period a year ago.
U.S. Pharmaceuticals Industry Analysis and Trends 2023: Report covers Competitive Landscape Of U.S. Pharma Companies
Browse Report [11]
Related Pharmaceutical Industry Articles
1. Global Pharmaceuticals Market Forecast: Drivers, Value Chain Analysis & Trends [23]
2. World’s Top 10 Pharmaceutical Companies by Revenue [24]
3. Top 15 Pharma Companies in India [25]
4. World's Top Selling Pharmaceutical Drugs and Manufacturers by Sales [26]
5. Top 6 Therapeutic Companies to Look out for Acute Renal Failure (Acute Kidney Injury) [27]
6. Top 10 Oncology Pharma Companies in the World [28]
7. Top 10 Antidiabetics Pharma Companies in the World [29]